Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating...
05.03.2015
- Adaptimmune announced the appointments of Dr. Rafael Amado as Chief Medical Officer and Adrian (Ad) Rawcliffe as Chief Financial Officer, with effect of March 16, 2015. Dr. Amado...
05.06.2014
- Adaptimmune, a biotechnology company developing TCR engineered T-cells to treat cancer, has begun a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for...
